T2 Biosystems Announces direcT2 Pivotal Clinical Trial of T2Candida Enrolling at All Clinical Sites

T2 Biosystems Announces direcT2 Pivotal Clinical Trial of T2Candida Enrolling at All Clinical Sites

September 9, 2013

--T2Candida Directly Detects Species-specific Candida from Whole Blood in Approximately Three Hours--

Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against Multiple Influenza Strains with Pandemic Potential

Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against Multiple Influenza Strains with Pandemic Potential

September 9, 2013

Broadly protective properties of VIS410, a novel engineered human antibody, presented at the Options for the Control of Influenza conference in Cape Town, South Africa

CAMBRIDGE, Mass., Sep 09, 2013 (BUSINESS WIRE) -- Visterra, Inc., developer of novel therapeutics to treat major infectious diseases, today announced that its Chief Medical Officer, Donna Ambrosino, M.D., presented data on VIS410 at the Options for the Control of Influenza, an international conference held every three years, taking place this year in Cape Town, South Africa on September 5-9, 2013.

Study Published in Nature Biotechnology Demonstrates Ability of Moderna's Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue

Study Published in Nature Biotechnology Demonstrates Ability of Moderna's Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue

September 8, 2013

Messenger RNA therapeutics™ successfully induced high-level, transient expression of VEGF-A protein in the heart, stimulating the growth of cardiovascular cells and improving heart function and survival in an animal model of myocardial infarction

Syros Pharmaceuticals Appoints Vicki L. Sato, Ph.D., to Board of Directors

Syros Pharmaceuticals Appoints Vicki L. Sato, Ph.D., to Board of Directors

September 5, 2013

WATERTOWN, Mass., Sep 05, 2013 (BUSINESS WIRE) -- Syros Pharmaceuticals, a life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, announced today the appointment of Vicki L. Sato, Ph.D., to its Board of Directors. Dr.

Flagship VentureLabs Launches Midori Renewables

Flagship VentureLabs Launches Midori Renewables

September 4, 2013

New Venture is Commercializing a Novel Catalytic Process to Convert Non-Food Biomass Into Sugar

Affinnova Reveals Bottle Design Trumps Taste in Vodka Brand War

Affinnova Reveals Bottle Design Trumps Taste in Vodka Brand War

September 4, 2013

Study Shows Package Design Plays Vital Role in Consumer Perception and Shelf Impact

Tetraphase Doses First Patient in Phase 3 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections

Tetraphase Doses First Patient in Phase 3 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections

September 3, 2013

- First of Two Planned Phase 3 Clinical Trials of Tetraphase's Lead Antibiotic Candidate Designed to Support Submission for Approval in Two Indications: Complicated Intra-abdominal Infections and Complicated Urinary Tract Infections -

The World Economic Forum Recognizes Four Flagship Ventures Portfolio Companies as Technology Pioneers for 2014

The World Economic Forum Recognizes Four Flagship Ventures Portfolio Companies as Technology Pioneers for 2014

August 28, 2013

Agios Pharmaceuticals, BIND Therapeutics, Oasys Water and Selecta Biosciences to be honored

36 Innovative Companies Recognized as World Economic Forum Technology Pioneers

36 Innovative Companies Recognized as World Economic Forum Technology Pioneers

August 27, 2013
  • 36 companies celebrated for pioneering technologies, which hold promise of transforming business and society
  • Technology Pioneers are selected annually by a high-level selection committee.
  • Since 2000, more than 550 companies have been selected as Technology Pioneers
  • Read their profiles and download the report at http://www.weforum.org/techpioneers

Seahorse Bioscience and the Cancer Research UK Beatson Institute Team Up Against Cancer

Seahorse Bioscience and the Cancer Research UK Beatson Institute Team Up Against Cancer

August 22, 2013

Novel technology will boost research into cancer metabolism

Billerica, MA, August 22, 2013 – Seahorse Bioscience will provide the Cancer Research UK Beatson Institute with its novel XF technology, which measures cell metabolism, to boost research to enable a greater understanding of cancer metabolism and its role in disease progression.